ArticleOncoimmunology2013
Arming NK cells with enhanced antitumor activity: CARs and beyond.
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Modern Advances in CARs Therapy and Creating a New Approach to Future Treatment.International journal of molecular sciences · 2022Review
- A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets.Frontiers in immunology · 2022Article
- Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy.Immunotherapy advances · 2022Review
- Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy.Stem cell research & therapy · 2021Review
- Article
- Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies.Clinical hematology international · 2019Review
- Magnetic Nanoparticles Attached to the NK Cell Surface for Tumor Targeting in Adoptive Transfer Therapies Does Not Affect Cellular Effector Functions.Frontiers in immunology · 2019Article
- Article
- Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.Frontiers in immunology · 2017Article
- Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.Cancer immunology, immunotherapy : CII · 2016Review
- Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective.Frontiers in immunology · 2014Review
- KIR/HLA immunogenetic background influences the evolution of hepatocellular carcinoma.Oncoimmunology · 2013Article
- Failure recovery of circulating NKG2DOncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer (NK) cells hold great promise for adoptive cancer immunotherapy. The antitumor activity of NK cells can be enhanced by the transgene driven expression of chimeric antigen receptors that facilitate the selective recognition and killing of malignant cells. Recent data from our laboratory suggest that NK cells may similarly be "armed" against neoplastic cells by the expression of cancer-specific granzyme B-containing fusion proteins that are released as soluble factors upon NK-cell activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.